Literature DB >> 20807977

Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.

Norio Asou, Eisaku Iwanaga, Tomoko Nanri, Hiroaki Mitsuya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20807977      PMCID： PMC2930974          DOI： 10.3324/haematol.2010.27656

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13).

Authors:  Juyoung Shin; Myungshin Kim; Dae-Bum Kim; Ju-Ok Yeom; Hyo-Jin Lee; Seok-Goo Cho
Journal:  Acta Haematol       Date:  2008-02-12       Impact factor: 2.195

2.  A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.

Authors:  Eisaku Iwanaga; Tomoko Nanri; Naofumi Matsuno; Toshiro Kawakita; Hiroaki Mitsuya; Norio Asou
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

Review 3.  Therapy-related myeloid neoplasms.

Authors:  Richard A Larson
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

4.  Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.

Authors:  Roberto Latagliata; Maria Concetta Petti; Susanna Fenu; Marco Mancini; Maria Antonietta Aloe Spiriti; Massimo Breccia; Gregorio A Brunetti; Giuseppe Avvisati; Francesco Lo Coco; Franco Mandelli
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

5.  A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study.

Authors:  Norio Asou; Yuji Kishimoto; Hitoshi Kiyoi; Masaya Okada; Yasukazu Kawai; Motohiro Tsuzuki; Kentaro Horikawa; Mitsuhiro Matsuda; Katsuji Shinagawa; Tohru Kobayashi; Shigeki Ohtake; Miki Nishimura; Masatomo Takahashi; Fumiharu Yagasaki; Akihiro Takeshita; Yukihiko Kimura; Masako Iwanaga; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

6.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

Authors:  Marianna David; Nicholas C P Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M Goldman; Francis Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A McArthur; Francois X Mahon; Giorgio Massimini; Junia Melo; Philippe Rousselot; Robin J Russell-Jones; John F Seymour; Graeme Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F Apperley
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

7.  Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.

Authors:  I Lobe; F Rigal-Huguet; A Vekhoff; B Desablens; D Bordessoule; C Mounier; A Ferrant; M Sanz; M Fey; C Chomienne; S Chevret; L Degos; P Fenaux
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

8.  A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.

Authors:  Tamara Intermesoli; Federica Delaini; Sara Acerboni; Silvia Salmoiraghi; Orietta Spinelli; Vittoria Guerini; Alessandro M Vannucchi; Silvia Mappa; Giuseppe Rossi; Valentina Rossi; Eros Di Bona; Simona Paratore; Alessandra Carobbio; Alessandro Rambaldi; Tiziano Barbui; Renato Bassan
Journal:  Br J Haematol       Date:  2009-09-04       Impact factor: 6.998

9.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors:  Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.